Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer

Anti-Cancer Drugs

Volumn 17, Issue 9, 2006, Pages 1081-1085

  Livi, Lorenzo ^a   Paiar, Fabiola ^a   Santini, Roberto ^a   De Luca Cardillo, Carla ^a   Galardi, Alessandra ^a   Di Cosmo, Dora ^a   Borghesi, Simona ^a   Agresti, Benedetta ^a   Nosi, Fabiano ^a   Gavilli, Sergio ^b   Biti, Gian Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Villanova Hospital of Firenze   (Italy)

Author keywords

Breast cancer; Neoadjuvant treatment; Oral chemotherapy

Indexed keywords

EPIRUBICIN; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; NEUTROPENIA; POLYNEUROPATHY; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR VOLUME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; FILGRASTIM; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOADJUVANT THERAPY; VINBLASTINE;

EID: 33748996185     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000231478.22901.6e     Document Type: Article

References (31)

1. Hortobagyi GN, Buzdar AU, Montague E, Romsdahl M. Neoadjuvant chemotherapy for primary breast cancer. In: Jacquillat C, Weil M, Khayat D, editors. Neo-adjuvant chemotherapy. Paris: Colloque INSERM/John Libbey Eurotext; 1986. pp. 186-196.
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82:1539-1545.
3. Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer. Ann Med 2000; 32:43-50.
4. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73:362-369.
5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
6. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003; 98:1150-1160.
7. Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: results of a randomised trial in a single centre. Ann Oncol 1991; 2:347-354.
8. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-2493.
9. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. Preliminary results of a randomised trial. Eur J Cancer 1994; 30A:645-652.
10. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12:336-341.
11. Vici P, Colucci G, Gebbia V, Amodio A, Giotta F, Belli F, et al. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 2002; 20:2689-2694.
12. Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M; Scandinavian Breast Group Trial (SBG9403). Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 22:2313-2320.
13. Ferrero JM, Namer M, Romaioli A. Neoadjuvant chemotherapy with a combination of vinorelbine and epirubicin in locally advanced breast cancer. Preliminary results of a phase II study [abstract] (preliminary results of a phase II study). Proc Am Soc Clin Oncol 1997; 16.
14. Chen C, Shen K, Lu J. The combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of local advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:57.
15. Chua S, Smith IE, A'Hern RP, Coombes GA, Hickish TF, Robinson AC, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/ cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol 2005; 16:1435-1441.
16. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. Oral vinorelbine phase I pharmacokinetics and absolute bioavailability study in patients with solid tumours. Ann Oncol 2001; 12:1643-1649.
17. Variol P, Nguyen L, Tranchand B, Puozzo C. A simultaneous oral/intravenous population pharmacokinetics model for vinorelbine. Eur J Clin Pharmacol 2002; 58:467-476.
18. Amadori D, Koralewski P, Tekiela A. Efficacy and safety of Navelbine oral (NVBo) in first line metastatic breast cancer (MBC). Eur J Cancer 2001; 37:S195 (abstr 713).
19. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21:35-40.
20. Serin D, Verrill M, Jones A, Delozier T, Coleman R, Kreuser ED, et al. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. Br J Cancer 2005; 92:1989-1996.
21. WHO. WHO handbook for reporting results of cancer treatment. Geneva: WHO; 1979.
22. Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19:4224-4237.
23. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95:681-695.
24. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
25. Shannon C, Smith I. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 2003; 45:77-90.
26. Blomqvist C, Hietanen P, Teerenhovi L, Rissanen P. Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer 1995; 31A:2406-2408; 903909.
27. Frampton JE, Keating GM. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia. BioDrugs 2005; 19:405-407.
28. Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 2005; 12:1635-1646.
29. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15:110-115.
30. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38:349-358.
31. DeMario M, Ratain M. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16:2557-2567.